Liver Cancer Drug Market Report 2026

Liver Cancer Drug Market Overview

• Liver Cancer Drug market size has reached to $2.62 billion in 2025 • Expected to grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 12.1% • Growth Driver: Rising Research And Development Investment Fueling The Growth Of The Market Due To Demand For Innovative And Targeted Therapies • Market Trend: Innovation In Liver Cancer Treatment Driving Market Growth Through Advanced Therapies And Precision Approaches • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Liver Cancer Drug Market?

Liver cancer drug refers to a class of pharmaceutical agents designed to combat malignant cell growth within a vital organ responsible for detoxification, metabolism, and nutrient storage. These drugs work by targeting the biological pathways that enable abnormal cells to grow, divide, and evade the body’s natural defense mechanisms. The main types of liver cancer drugs include hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Hepatocellular carcinoma (HCC) refers to the most common type of primary liver cancer, meaning it originates in the liver rather than spreading from another organ. It includes various therapies such as targeted therapy, immunotherapy, chemotherapy, and others, administered orally or through injection. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Liver Cancer Drug Market Growth Forecast?

The liver cancer drug market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing approvals of novel immunotherapies, rising investments in oncology R&D, expansion of personalized cancer treatment approaches, growing demand for combination therapies, increasing focus on early-stage liver cancer treatment. Major trends in the forecast period include increasing adoption of targeted liver cancer therapies, rising use of immunotherapy combinations, expansion of precision oncology drug development, growing focus on biomarker-based treatment selection, enhanced integration of companion diagnostics.

Global Liver Cancer Drug Market Segmentation

1) By Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Other Types 2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies 3) By Route Of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Hepatocellular Carcinoma: Targeted Therapy, Immunotherapy, Chemotherapy, Combination Therapy 2) By Cholangio Carcinoma: Targeted Therapy, Chemotherapy, Immunotherapy 3) By Hepatoblastoma: Chemotherapy, Targeted Therapy, Immunotherapy, Surgical Adjuvants 4) By Other Types: Chemotherapy, Targeted Therapy, Experimental Or Off-label Therapies, Supportive Care Medications

What Is The Driver Of The Liver Cancer Drug Market?

The increasing research and development are expected to propel the growth of the liver cancer drug market going forward. Research and development involve a structured approach to exploring, creating, and evaluating new products, technologies, or methods with the goal of expanding knowledge and introducing innovative solutions to the market. Research and development are rising due to the increasing demand for innovation and technological advancements across industries, driving companies to invest in new products and improvements to stay competitive. Research and development support liver cancer drugs by enabling the discovery of targeted therapies that improve treatment effectiveness and reduce damage to healthy liver tissue. For instance, in September 2024, according to Cancer Research UK, a UK-based cancer research organization, $533 million (£399 million) was invested in cancer research in the 2023-24 financial year, with $124 million (£93 million) directed toward research applicable to all cancer types and $112 million (£84 million) allocated to basic studies focused on understanding cancer’s fundamental biology. Therefore, the increasing research and development are driving the growth of the liver cancer drug industry.

Key Players In The Global Liver Cancer Drug Market

Major companies operating in the liver cancer drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company Limited, Hetero Drugs Limited, Sun pharma, Eisai Company Limited, Genentech Incorporated, Ipsen Société Anonyme, Cipla Limited, Dr. Reddy’s Laboratories Limited, BeiGene Ltd., Exelixis Incorporated, Natco Pharma Limited, MacroGenics Inc.

Global Liver Cancer Drug Market Trends and Insights

Major companies operating in the liver cancer drug market are focusing on developing innovative solutions, such as advanced therapy for liver cancer treatment, to enhance treatment precision and patient outcomes. Advanced therapy for liver cancer refers to innovative approaches such as immunotherapy, targeted therapy, gene therapy, CAR-T cell therapy, and minimally invasive procedures such as TACE and ablation, aimed at improving efficacy and precision in treating liver cancer. For instance, in November 2023, Terumo India, an India-based manufacturer of medical devices, introduced advanced Balloon-TACE therapy for liver cancer treatment in India, featuring two innovative devices, Occlusafe and LifePearl, designed to improve the precision and effectiveness of transcatheter arterial chemoembolization (TACE). This therapy targets hepatocellular carcinoma, the most common liver cancer in India, by delivering chemotherapy directly to tumors while minimizing damage to healthy tissue and preserving liver function.

What Are Latest Mergers And Acquisitions In The Liver Cancer Drug Market?

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. As a result of acquiring Surface Oncology, Coherus has expanded its immuno-oncology pipeline to include several antibody-based immunotherapy candidates. These therapies aim to strengthen both innate and adaptive immune responses, ultimately improving treatment outcomes for cancer patients. Surface Oncology Inc. is a US-based manufacturer of liver cancer drugs.

Regional Outlook

North America was the largest region in the liver cancer drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Liver Cancer Drug Market?

The liver cancer drug market consists of revenues earned by entities by providing services such as clinical trial management, pharmacovigilance services, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer drug market also includes sales of monoclonal antibodies, hormonal therapy drugs, gene therapy products, and liver-specific drug delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.